In our study, endostatin performed with a better prediction value than NGAL so it seems that endostatin is a more promising biomarker to predict failure to recover, despite the different population, diagnostic criteria of AKI and predictive time window. This evidence concerns the gene COL18A1 and acute kidney injury.